Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP4 | P49662 | 1/20 | 0.47 |
| ▸ | CASP5 | P51878 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7204490 | 0.88 | HPGD (0.46) | LSSHPGDCYP2D6KDM4ECYP3A4 | |
| SCHEMBL28269086 | 0.87 | LSS (0.66) | LSSHPGDCYP2D6KDM4ECYP3A4 | |
| SCHEMBL3994683 | 0.83 | HRH3 (0.67) | LSSHPGDCYP2D6KDM4ECYP3A4 | |
| SCHEMBL10525513 | 0.81 | HRH3 (0.71) | LSSHPGDCYP2D6KDM4ECYP3A4 | |
| SCHEMBL13442 | 0.81 | HRH3 (0.71) | LSSHPGDCYP2D6KDM4ECYP3A4 | |
| SCHEMBL2208141 | 0.81 | HRH3 (0.71) | LSSHPGDCYP2D6KDM4ECYP3A4 | |
| SCHEMBL664820 | 0.79 | LSS (0.53) | LSSHPGDCYP2D6KDM4ECYP3A4 | |
| SCHEMBL28277353 | 0.79 | MAOA (0.46) | LSSHPGDCYP2D6KDM4ECYP3A4 | |
| SCHEMBL60814 | 0.78 | SIGMAR1 (0.74) | KDM4ECYP3A4POLBSIGMAR1 | |
| SCHEMBL209327 | 0.78 | HPGD (0.70) | LSSHPGDCYP2D6CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102153544-A | Preparation method and application of novel tyrosine kinase inhibitors | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2011-08-17 | — | — | CN | claimed |
| CN-1984892-A | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-06-20 | — | — | CN | claimed |
| CN-1984655-A | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-06-20 | — | — | CN | claimed |
| CN-1960975-A | Substituted pyridones as poly (ADP-ribose) polymerase (PARP) inhibitors | AVENTIS PHARMA INC (US) | 2007-05-09 | — | — | CN | claimed |
| US-7186710-B2 | Phthalazinones | ALTANA PHARMA AG (DE) | 2007-03-06 | — | — | US | claimed |
| EP-1732896-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2005097750-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20040127707-A1 | PDE4/7 inhibitors useful in treatment of airway disorders, autoimmune system disorders, skin disorders, arthritis, nerve system disorders | ALTANA PHARMA AG (DE) | 2004-07-01 | — | — | US | claimed |
| CN-1503792-A | Phthalazinones | ��̹��ҽҩ��˾ | 2004-06-09 | — | — | CN | claimed |
| EP-1385848-A2 | PHTALAZINONES DERIVATIVES USEFUL AS PDE4/7 INHIBITORS | ALTANA Pharma AG (DE) | 2004-02-04 | — | — | EP | claimed |
| WO-2002085906-A2 | PHTHALAZINONES DERIVATIVES USEFUL AS PDE4/7 INHIBITORS | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | claimed |
| CN-102153544-B | Preparation method and application of novel tyrosine kinase inhibitors | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2015-04-29 | — | — | CN | disclosed |
| CN-1984655-B | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB CO. (US) | 2011-11-30 | — | — | CN | disclosed |
| CN-102153544-A | Preparation method and application of novel tyrosine kinase inhibitors | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2011-08-17 | — | — | CN | disclosed |
| US-7834015-B2 | treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV skin damage, and as chemosensitizers or radiosensitizers for cancer treatment | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-11-16 | — | — | US | disclosed |
| WO-2002085906-A2 | PHTHALAZINONES DERIVATIVES USEFUL AS PDE4/7 INHIBITORS | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | disclosed |
| EP-0625507-B1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
| CN-1041363-A | PROCESS FOR PREPARING IMIDAZOLE ANTIARRHYTHMICS | MERRELL DOW PHARMA (US) | 1990-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127707-A1 | PDE4/7 inhibitors useful in treatment of airway disorders, autoimmune system disorders, skin disorders, arthritis, nerve system disorders | PDE4A, PDE4B, PDE7B | LSS 1506/4885HPGD 1329/4885CYP2D6 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.